Salmon Nasal Cartilage Proteoglycan Ameliorate Joint Pain and Cartilage Degradation by Regulating Catabolic and Anabolic Homeostasis in MIA-Induced Osteoarthritis
Nutrients · 2026
DOI: 10.3390/nu18010176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2026. Verfasst von Min Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chungbuk National University, 194-21 Osongsaengmyoung 1-ro, Osong-eup, Heungduk-gu, Cheongju 29160, Chungbuk, Republic of Korea. Hauptthemen laut MEDLINE: Proteoglycans, Osteoarthritis, Nasal Cartilages, Cartilage, Articular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Chungbuk Regional Innovation System & Education Center, The National Research Foundation of Korea (NRF), Regional Innovation System & Education (RISE) program through the Chungbuk Regional Innovation System & Education Center.
Abstract (Originalsprache)
Background/Objectives: Osteoarthritis (OA) is a pervasive chronic joint disease characterized by the triad of persistent articular cartilage degeneration, debilitating synovial inflammation, and sustained chronic pain. Although salmon nasal cartilage proteoglycan (SPG) is recognized for supporting joint health, the precise molecular mechanism underlying its effects during OA progression remains to be fully elucidated. This study evaluated the therapeutic efficacy of SPG using a monosodium iodoacetate (MIA)-induced mouse model.
Methods
A total of 180 male C57BL/6J mice (six-week-old) were utilized, organized into three independent cohorts to analyze distinct analytical endpoints: (1) pain assessment, histology, and immunohistochemistry; (2) mRNA expression analysis for early-stage OA (Day 3); and (3) mRNA expression analysis for the late-stage OA (Day 28). All subjects received daily oral treatment via gavage, commencing 5 days prior to OA induction and continuing until the designated experimental termination points (either Day 3 or Day 28). Each cohort comprised five experimental groups (n = 10–12 per group): a saline-injected Sham group, an MIA-induced Control group, a positive comparator receiving celecoxib (CLX, 20 mg/kg/day), and two groups administered SPG at a dose of 50 or 100 mg/kg/day.
Results
Our findings demonstrated that SPG, particularly at the 100 mg/kg dose, significantly mitigated joint pain symptoms, performing comparably to CLX. Histopathological assessments confirmed that SPG effectively preserved the structural integrity of the cartilage matrix and substantially reduced pathological damage, as evidenced by lower Mankin scores. Mechanistically, SPG treatment led to a marked downregulation of degradative enzymes, including matrix metalloproteinase-3 (MMP-3) and a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS-4), while concurrently normalizing the levels of tissue inhibitors of metalloproteinases (TIMPs). Furthermore, SPG prevented the aberrant, over-compensatory expression of anabolic markers such as SRY-box transcription factor 9 (SOX-9), type II collagen alpha 1 chain (COL2A1), and aggrecan (ACAN) typically observed in the disease’s later stages. While SPG demonstrated a limited impact on broadly pro-inflammatory cytokine profiles, it specifically and significantly reduced interleukin-6 (IL-6) gene expression during the chronic phase.
Conclusions
These results suggest that SPG serves as a promising natural agent that maintains articular homeostasis by balancing matrix metabolic pathways, positioning it as a scientifically validated functional food candidate for the management of joint health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Chungbuk National University, 194-21 Osongsaengmyoung 1-ro, Osong-eup, Heungduk-gu, Cheongju 29160, Chungbuk, Republic of Korea.
- R&D Center, Naturetech Inc., 450-86 Maebong-ro, Byeongcheon-myeon, Dongnam-gu, Cheonan 31257, Chungnam, Republic of Korea.
- Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, 1760 Haygood Drive NE, Atlanta, GA 30306, USA.
ORCID-Profile: Min Yu, Sang Bae Han, Hyun Jin Kim, Seon Gil Do, Hanjoong Jo, Dong Ju Son
Förderung
- the Chungbuk Regional Innovation System & Education Center
- The National Research Foundation of Korea (NRF)
- Regional Innovation System & Education (RISE) program through the Chungbuk Regional Innovation System & Education Center
- Ministry of Education (MOE) and the Chungcheonbuk-do
- National Research Foundation of Korea
- Korean government
Zitieren
APA
Yu, M., Jo, S. E., Son, Y. B., Kim, Y. J., Seo, Y., Han, S. B., Kim, H. J., Do, S. G., Jo, H., & Son, D. J. (2026). Salmon Nasal Cartilage Proteoglycan Ameliorate Joint Pain and Cartilage Degradation by Regulating Catabolic and Anabolic Homeostasis in MIA-Induced Osteoarthritis. Nutrients. https://doi.org/10.3390/nu18010176
Vancouver
Yu M, Jo SE, Son YB, Kim YJ, Seo Y, Han SB, et al. Salmon Nasal Cartilage Proteoglycan Ameliorate Joint Pain and Cartilage Degradation by Regulating Catabolic and Anabolic Homeostasis in MIA-Induced Osteoarthritis. Nutrients. 2026. doi:10.3390/nu18010176
BibTeX
@article{Yu2026,
author = {Yu, Min and Jo, So Eun and Son, Young Bae and Kim, Ye Jin and Seo, Youngsik and Han, Sang Bae and Kim, Hyun Jin and Do, Seon Gil and Jo, Hanjoong and Son, Dong Ju},
title = {Salmon Nasal Cartilage Proteoglycan Ameliorate Joint Pain and Cartilage Degradation by Regulating Catabolic and Anabolic Homeostasis in MIA-Induced Osteoarthritis},
journal = {Nutrients},
year = {2026},
doi = {10.3390/nu18010176}
}
EUVIMED